## Adverse Effects and Drug Interactions of Hypolipidemics ### Overview of Safety Profiles | Drug Class | Major Adverse Effect | Drug Interaction Risk | Mechanism | |------------|--------------------|-----------------------|-----------| | Statins | Myopathy, rhabdomyolysis | High (CYP3A4 substrate) | Muscle CoQ10 depletion | | Fibrates | Myopathy (especially + statin) | Moderate (CYP3A4 inhibitor) | Statin accumulation | | Ezetimibe | Hepatitis (rare) | Low | Minimal CYP450 involvement | | PCSK9 inhibitors | Injection site reactions | Very low | Monoclonal antibody; no CYP450 | | Nicotinic acid | Flushing, hyperuricemia | Low | Direct metabolic effects | ### Why Option 2 (Ezetimibe) Is Wrong **Key Point:** Ezetimibe does NOT inhibit hepatic bilirubin uptake. It selectively inhibits cholesterol absorption in the small intestine by blocking the Niemann-Pick C1-like 1 (NPC1L1) transporter. **High-Yield:** Ezetimibe's hepatotoxicity (rare) is not due to cholestasis or bilirubin metabolism. Elevated liver enzymes are uncommon and usually mild. The drug is safe in hepatic disease and does not cause clinically significant bilirubin-related cholestasis. **Clinical Pearl:** Ezetimibe is often combined with statins because it works via a different mechanism (intestinal absorption inhibition vs. hepatic synthesis inhibition) and has minimal drug interactions. The concern with ezetimibe is myopathy when combined with statins—not hepatic bilirubin handling. **Warning:** Do not confuse ezetimibe's mechanism with that of bile acid sequestrants (which bind bile acids in the intestine) or with drugs that affect bilirubin metabolism (e.g., rifampicin, which induces glucuronidation). [cite:Harrison 21e Ch 395]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.